-
TOMORROW, Trends in ROS1 Mutated Non-Small Cell Lung Cancer Webinar MOASC News/MOASC Programs
-
7th Annual Oncology Summit & Research Symposium slides MOASC News
-
Nurse Practitioners can practice without physician supervision California News
-
April 1 brings new changes Medicare News/CMS News
|
|
MOASC Board of Directors would like to thank those who joined us on Saturday at the 7th Annual Oncology Summit & Research Symposium. MOASC President, Ashkan Lashkari, MD, welcomed the more than 150 in attendance and reviewed MOASC’s continued oncology presence in California. Anthony Nguyen, MD, MOASC Board Member, Program Director and Moderator introduced presentations by physicians: Sumanta Pal, MD, FASCO (City of Hope) GU cancers; Ryotaro Nakamura, MD (City of Hope) CAR-T/Transplant; Amrita Krishnan, MD (City of Hope) Myeloma; Sai-Hong Ignatius Ou, MD, PhD (UCI) Lung cancer; Janice Lu, MD, PhD (USC) Breast cancer & scientist Trey Ideker, PhD (UCSD) Cancer Cell Map Initiative. Industry presentations were made by: Astra Zeneca, Aveo Oncology, Bristol Myers Squibb, Grail Inc., Incyte, Jazz Pharmaceuticals, PayGround, Pfizer Oncology and Takeda.
MOASC would like to thank: Astra Zeneca, BeiGene, Bristol Myers-Squibb, Grail, Incyte, Jazz Pharmaceuticals, Pfizer and Takeda; AbbVie, Daiichi Sankyo and SeaGen; Janssen and Merck; ADC Therapeutics, Astellas, Gilead and Guardant Health; Advance Accelerator Applications, Aveo Oncology, Biotheranostics, Eisai, Glaxo Smith Kline, Macrogenics, Morphosys, Myovant Sciences, Pharmacosmos Therapeutics, Pharmacyclics, Sanofi, Sobi and Tempus for their support of this program & MOASC.
Slides and handouts of presentation are available, upon request at moasc@moasc.org
|
|
MOASC Programs - Save the Dates - All Times are Pacific
|
|
TOMORROW! March 30, 2022, MOASC presents their Lung Cancer Series webinar on the Trends in ROS1 Mutated Non-Small Cell Lung Cancer. Join us for a lively discussion with Moderator Hatim Husain, MD, UC San Diego and panelists Sai-Hong I. Ou, M.D., PhD, UCI Health and Joel Neal, M.D., PhD, Stanford Health Care. This is a great opportunity for a collaborative discussion with experts and colleagues. Pharmaceutical representatives interested in attending, please email Wendy Alfaro at moasc@moasc.org.
|
|
MOASC presents, Disparities in Clinical Trials, clinical webinar, Thursday, April 7, 5:30pm PDT. This presentation will provide a high level overview of clinical trials, discuss disparities in breast cancer and summarize initiatives to better engage with patients. Presented by: Adeline Wang, MD, PhD and Venky Kashi, PhD. Sponsored by Pfizer.
|
|
Career News
Sign up now to receive the MOASC Job Flash™! Please activate your new job alert.
|
|
MOASC Clinical Trial Database is on the MOASC website at www.moasc.org
|
|
California senate president pro tempore Toni Atkins (D-San Diego) has introduced SB 1375 to clarify that NPs who have been practicing for three years or more would satisfy the transition requirement. The Transition Requirement focuses on California nurse practitioners working with minimal supervision in clinical settings under the supervision of physicians for several years, who fully understand the care needs and interventions required to help a patient in their health journey, and can safely practice without physician supervision. If this bill doesn’t pass, the transition-to-practice requirement will then need to be defined by the Board of Registered Nurses (BRN) regulation. In 2020, California governor Gavin Newsom and the state legislature enacted a law (AB 890) that will allow nurse practitioners to practice without physician supervision once they meet certain criteria. Research has shown that the quality of primary care provided by NPs is similar to care delivered by physicians. Most states already allow NPs to practice independently, and access to primary care is greater in those states. California faces a projected shortfall of 4,100 primary care clinicians over the next 10 years, so more providers are needed to meet demand.
|
|
After twice refusing to consider GOP Assemblymember Kevin Kiley of Rocklin’s bill to suspend California’s excise gas tax for six months, a key Assembly committee passed it yesterday, after gutting the contents and inserting an entirely new measure from Democratic Assemblymember Alex Lee of San Jose. Lee’s amendments would, among other things, impose a new tax on gas suppliers when the price of a gallon of gas is “abnormally high” compared to the cost of a barrel of crude oil, and send the tax revenue back to California drivers via a rebate.
|
|
March 30, 2022 - Telehealth Provider Enrolling in Medicare
Learn telehealth regulations and how to enroll in Medicare as a provider or supplier. Learn about eligible providers, originating sites, distant site practitioners, and what type of equipment for communication is necessary for compliance.
|
|
April 6, 2022, Physician Assistants and Practice Ownership Webinar includes: Physician Assistant Ownership Interest, Physician Assistant Enrolling in Medicare, Physician Assistant Enrolling as a Sole Proprietor, CMS 855I Initial Enrollment as a Physician Assistant, CMS 855 B Initial Enrollment as a Sole Owner - Physician Assistant, Electronic Funds Transfer Agreement, and Physician Assistant accepting reassignment as the employer.
|
|
April 1 brings new changes in HCPCS drug codes, Medicare drug allowables, HOPPS, “buy & bill,” and Sequestration returns to minus 1%.
|
|
CMS introduced bundled payment models over the past decade, including the current BPCI-A (Bundled Payment for Care Improvement - Advanced) program, which has proven effective in reigning in acute episode spending, particularly across post-acute settings where costs have historically been highly variable. CMS has announced they are exploring transitioning the BPCI-A program from voluntary to mandatory participation to expand its reach. In this new whitepaper from Sound Physicians, the authors explore the importance of hospital-physician alignment and the case for making physicians active participants with sufficient incentives to encourage professional stewardship around cost decisions under Mandatory Bundled Payments (MBP).
|
|
President Biden proposed a $5.8 trillion budget March 28 for fiscal year 2023, which includes funding for healthcare. A portion of the healthcare funding is allocated to the Cancer Moonshot initiative, which proposes several investments across the FDA, CDC, National Cancer Institute and Advanced Research Projects Agency for Health. The initiative aims to reduce the cancer death rate by 50 percent over the next 25 years.
|
|
An analysis published in The Lancet found US prices for 12 cancer drug classes rose after market launch from 2009 to 2020 even if market competition increased, while prices for similar drugs in Germany and Switzerland generally declined over time or did not increase more than the rate of inflation.
|
|
Determining what your business needs for HIPAA is confusing. This checklist is designed to help guide you through some of the most overlooked components of a total HIPAA compliance program. Hopefully, you’ll already be able to check each of these items off your list, but if you’re like most other healthcare businesses, you are likely missing some essential parts of HIPAA.
|
|
Merck & Co., Inc., have provided a communication guide, Unique Considerations for Talking to Patients With Triple-Negative Breast Cancer (TNBC) which is intended to help the physician address and reduce disparities in health equity needs by initiating and navigating discussions with women who may face challenges and barriers to care. Social determinants of health (SDOH) are conditions in the environments where people are born, live, work, and age that affect a wide range of health care-related outcomes.1 A considerable proportion of patients with TNBC are younger, premenopausal women who may face barriers to care due to SDOH.2 Merck & Co., Inc.’s goal is to ensure that all women in the United States have access to equitable health care, which may lead to a healthy life, regardless of their income, education, ethnicity, or race.
References: 1. Tucker-Seeley RD. Social determinants of health and disparities in cancer care for Black people in the United States.
JCO Oncol Pract. 2021;17(5):261–263. doi:10.1200/OP.21.00229 2. Scott LC, Mobley LR, Kuo T-M, Il’yasova D. Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistics database, 2010 through 2014. Cancer. 2019;125(19):3412–3417. doi: 10.1002/cncr.32207
|
|
ADC Therapeutics informed MOASC that starting April 1, 2022 a permanent J-Code has been issued for ZYNLONTA® (J9359 injection loncastuximab tesirine-lpyl 0.075mg). Please use this permanent J-Code for all dates on or after April 1, 2022. It is important to bill the number of units administered. Please note that the number of milligrams administered will vary based on patient weight.
|
|
The Medical Oncology Association of Southern California (MOASC) is a leading oncology society that advances and protects the ability of cancer patients to obtain, and the ability of the oncology physicians to provide, optimal cancer care. The material contained in the California Oncology Weekly is intended as general information for MOASC members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the California Oncology Weekly may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in California Oncology Weekly should not be used as a substitute for such advice. This publication provides a summary of regulations affecting oncology and its business practices. Reading this newsletter does not substitute for understanding regulations and verifying the validity of every claim. This information is time-sensitive and is subject to change. MOASC accepts no liability for any statements or articles herein. CPT codes are owned and trademarked by the American Medical Association. All Rights Reserved.
|
|
|
|
|
|
|
